Company Analysis AgeX Therapeutics, Inc.
1. Summary
Advantages
- Price (11.1 $) is less than fair price (23.36 $)
- Current debt level 36.48% is below 100% and has decreased over 5 years from 161.54%.
Disadvantages
- Dividends (0%) are below the sector average (1.36%).
- The stock's return over the last year (0%) is lower than the sector average (2.68%).
- The company's current efficiency (ROE=-270.67%) is lower than the sector average (ROE=-74.13%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| AgeX Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -37.3% | 0.8% |
| 90 days | 0% | 7.2% | 4.9% |
| 1 year | 0% | 2.7% | 17.3% |
AGE vs Sector: AgeX Therapeutics, Inc. has slightly underperformed the "Healthcare" sector by -2.68% over the past year.
AGE vs Market: AgeX Therapeutics, Inc. has significantly underperformed the market by -17.26% over the past year.
Stable price: AGE is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: AGE with weekly volatility of 0% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (11.1 $) is lower than the fair price (23.36 $).
Price significantly below the fair price: The current price (11.1 $) is 110.5% lower than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-0.81) is lower than that of the sector as a whole (142.19).
P/E vs Market: The company's P/E (-0.81) is lower than that of the market as a whole (73.05).
5.3. P/BV
P/BV vs Sector: The company's P/BV (0.079) is lower than that of the sector as a whole (18.07).
P/BV vs Market: The company's P/BV (0.079) is lower than that of the market as a whole (20.45).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (2.98) is lower than that of the sector as a whole (14.7).
P/S vs Market: The company's P/S indicator (2.98) is lower than that of the market as a whole (30.65).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-0.45) is lower than that of the sector as a whole (61.62).
EV/Ebitda vs Market: The company's EV/Ebitda (-0.45) is lower than that of the market as a whole (36.12).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 9.03% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (9.03%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-74.62%).
6.4. ROE
ROE vs Sector: The company's ROE (-270.67%) is lower than that of the sector as a whole (-74.13%).
ROE vs Market: The company's ROE (-270.67%) is lower than that of the market as a whole (51.58%).
6.6. ROA
ROA vs Sector: The company's ROA (-123.72%) is lower than that of the sector as a whole (6.62%).
ROA vs Market: The company's ROA (-123.72%) is lower than that of the market as a whole (11.19%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (21.38%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (45.09%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.36%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
